Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | Epidermal growth factor receptor | ||
Ligand | BDBM50599335 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEMBL_2229997 (CHEMBL5143769) | ||
IC50 | 38±n/a nM | ||
Citation | Shaikh, M; Shinde, Y; Pawara, R; Noolvi, M; Surana, S; Ahmad, I; Patel, H Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer. J Med Chem65:1008-1046 (2022) [PubMed] Article | ||
More Info.: | Get all data from this article, Assay Method | ||
Epidermal growth factor receptor | |||
Name: | Epidermal growth factor receptor | ||
Synonyms: | EGF Receptor Substrate | EGFR | EGFR_HUMAN | ERBB | ERBB1 | Epidermal Growth Factor Receptor Tyrosine Kinase | Epidermal Growth Factor Receptor erbB-1 | Epidermal Growth Factor Receptor, ErbB-1 | Epidermal growth factor receptor (EGFR) | Epidermal growth factor receptor (HER1) | HER1 | Protein-Tyrosine Kinase Erbb-1 | Proto-oncogene c-ErbB-1 | Receptor tyrosine-protein kinase ErbB-1 | Tyrosine-Protein Kinase ErbB-1 | ||
Type: | Receptor Kinase Domain | ||
Mol. Mass.: | 134279.59 | ||
Organism: | Homo sapiens (Human) | ||
Description: | P00533 | ||
Residue: | 1210 | ||
Sequence: |
| ||
BDBM50599335 | |||
n/a | |||
Name | BDBM50599335 | ||
Synonyms: | CHEMBL5194245 | ||
Type | Small organic molecule | ||
Emp. Form. | C36H42ClN5O2 | ||
Mol. Mass. | 612.204 | ||
SMILES | CCC(=O)N[C@H]1CC[C@@H](CC1)n1c2cc(Nc3ccc(N4CCN(C)CC4)c(C)c3)ccc2cc(-c2ccccc2Cl)c1=O |r,wU:5.4,wD:8.11,(4,-6.54,;2.66,-5.77,;2.66,-4.23,;4,-3.46,;1.33,-3.46,;1.33,-1.92,;-0,-1.15,;-0,.39,;1.33,1.16,;2.66,.39,;2.66,-1.15,;1.33,2.7,;-0,3.47,;-1.33,2.7,;-2.67,3.46,;-4,2.69,;-4,1.15,;-2.67,.38,;-2.67,-1.15,;-4,-1.92,;-4,-3.46,;-2.67,-4.24,;-2.67,-5.77,;-4,-6.55,;-4,-8.09,;-5.34,-5.78,;-5.34,-4.24,;-5.33,-1.16,;-6.66,-1.93,;-5.34,.38,;-2.67,5.01,;-1.33,5.78,;-0,5.01,;1.33,5.78,;2.66,5.01,;4,5.78,;4,7.32,;5.33,8.09,;6.66,7.31,;6.66,5.78,;5.34,5.01,;5.34,3.46,;2.66,3.47,;4,2.7,)| | ||
Structure |